糖心vlog传媒

logo

Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market is segmented by Type of Cancer (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, Uterine Sarcoma), by Product, and Geography.

Home Market Analysis Healthcare Research Device Drug Combination Research Diagnostics and Therapeutics Research Oncology Research APAC Uterine Cancer Therapeutics & Diagnostics Market

APAC Uterine Cancer Therapeutics & Diagnostics Market Size

View Global Report
Uterine Sarcoma Market Trends
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 2.50 %

Major Players

Asia Pacific Uterine Cancer Therapeutics & Diagnostics Market Key Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of APAC Uterine Cancer Therapeutics & Diagnostics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

APAC Uterine Cancer Therapeutics & Diagnostics Market Analysis

The Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market is expected to register a CAGR of 2.5% during the forecast period. The major factors driving the growth of the market in the Asia region is due to growing awareness about Uterine diseases and their available therapies, increasing health care expenditure and innovation in drug development, and subsequent technological advancements.

According to Cancer Australia, estimated that in 2016, there were about 527 deaths from uterine cancer in Australia. In 2019, it was estimated at around 562 deaths. In addition, it also stated that the risk of a female dying from uterine cancer will be 1 in 205.

Furthermore, governments are provoking awareness programs in certain Asia-Pacific regions. With the growing focus of the government and the healthcare providers, it has been indicated that the market will grow rapidly over the forecast period.

APAC Uterine Cancer Therapeutics & Diagnostics Market Trends

This section covers the major market trends shaping the APAC Uterine Cancer Therapeutics & Diagnostics Market according to our research experts:

Endometrial Adenocarcinoma is Expected to Witness Highest Growth Over the Forecast Period in the Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market

The major factors driving the growth of the segment is due to the growing burden of endometrial adenocarcinoma. For instance, as per Cancer Australia, in 2019, it is estimated that the age-standardized incidence rate of uterine cancer was about 20 cases per 100,000 females in Australia. The incidence rate for uterine cancer was expected to increase with age, peaking at age group 65鈥�69.

Furthermore, as per the Journal of Gynecological Oncology 2020, endometrial cancer is a major gynecologic malignancy with the highest rate among patients with gynecologic malignant tumors in Japan. In Japan, the age-adjusted mortality rate of endometrial cancer was 2.0 in 2017. In addition, in Australia, there were about 3,115 (4.7%) new cases of uterine cancer diagnosed in 2019 as per Cancer Australia. Thus, owing to the above factors the segment is expected to show growth in the coming years.

Uterine Sarcoma Market Size

APAC Uterine Cancer Therapeutics & Diagnostics Industry Overview

The Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market is consolidated competitive and most of the companies dealing with this market are the global players. However, with the rising technological advancements, smaller companies are also focusing on market penetration and are taking efforts to grab enough market share. Some of the companies involved in the market are Merck & Co., Inc, Eisai.Co.Ltd, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Siemens Healthcare Inc, GlaxoSmithKline Plc and Novartis AG.

APAC Uterine Cancer Therapeutics & Diagnostics Market Leaders

  1. Merck & Co., Inc

  2. Eisai.Co.Ltd

  3. Abbott Laboratories

  4. F. Hoffmann-La Roche Ltd

  5. Takeda Pharmaceutical Company Limited

*Disclaimer: Major Players sorted in no particular order

Merck & Co., Inc, Eisai.Co.Ltd, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited
Need More Details on Market Players and Competitors?
Download PDF

APAC Uterine Cancer Therapeutics & Diagnostics Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Awareness 糖心vlog传媒 Uterine Diseases and Their Available Therapies

      2. 4.2.2 Increasing Health Care Expenditure

      3. 4.2.3 Innovation in Drug Development and Subsequent Technological Advancements

    3. 4.3 Market Restraints

      1. 4.3.1 Low Success Rate in Clinical Trials for Cancer Drugs

      2. 4.3.2 High Cost Associated With the Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Cancer Type

      1. 5.1.1 Endometrial Adenocarcinoma

      2. 5.1.2 Adenosquamous Carcinoma

      3. 5.1.3 Papillary Serous Carcinoma

      4. 5.1.4 Uterine Sarcoma

    2. 5.2 By Product

      1. 5.2.1 Therapeutics

        1. 5.2.1.1 Surgery

        2. 5.2.1.2 Immunotherapy

        3. 5.2.1.3 Radiation Therapy

        4. 5.2.1.4 Chemotherapy

        5. 5.2.1.5 Other Therapeutics

      2. 5.2.2 Diagnostics

        1. 5.2.2.1 Biopsy

        2. 5.2.2.2 Pelvic Ultrasound

        3. 5.2.2.3 Hysteroscopy

        4. 5.2.2.4 Dilation and Curettage

        5. 5.2.2.5 CT Scan

    3. 5.3 Geography

      1. 5.3.1 Asia-Pacific

        1. 5.3.1.1 China

        2. 5.3.1.2 Japan

        3. 5.3.1.3 India

        4. 5.3.1.4 Australia

        5. 5.3.1.5 South Korea

        6. 5.3.1.6 Rest of Asia-Pacific

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Merck & Co., Inc

      2. 6.1.2 Eisai.Co.Ltd

      3. 6.1.3 Abbott Laboratories

      4. 6.1.4 F. Hoffmann-La Roche Ltd

      5. 6.1.5 Takeda Pharmaceutical Company Limited

      6. 6.1.6 Siemens Healthcare Inc

      7. 6.1.7 GlaxoSmithKline Plc

      8. 6.1.8 Novartis AG

    2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

APAC Uterine Cancer Therapeutics & Diagnostics Industry Segmentation

As per the scope of the report, uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. The Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market is segmented by type of cancer, product, and geography.

By Cancer Type
Endometrial Adenocarcinoma
Adenosquamous Carcinoma
Papillary Serous Carcinoma
Uterine Sarcoma
By Product
Therapeutics
Surgery
Immunotherapy
Radiation Therapy
Chemotherapy
Other Therapeutics
Diagnostics
Biopsy
Pelvic Ultrasound
Hysteroscopy
Dilation and Curettage
CT Scan
Geography
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Need A Different Region Or Segment?
Customize Now

APAC Uterine Cancer Therapeutics & Diagnostics Market Research FAQs

The APAC Uterine Cancer Therapeutics & Diagnostics Market is projected to register a CAGR of 2.5% during the forecast period (2024-2029)

Merck & Co., Inc, Eisai.Co.Ltd, Abbott Laboratories, F. Hoffmann-La Roche Ltd and Takeda Pharmaceutical Company Limited are the major companies operating in the APAC Uterine Cancer Therapeutics & Diagnostics Market.

The report covers the APAC Uterine Cancer Therapeutics & Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the APAC Uterine Cancer Therapeutics & Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

APAC Uterine Cancer Therapeutics & Diagnostics Industry Report

Statistics for the 2024 APAC Uterine Cancer Therapeutics & Diagnostics market share, size and revenue growth rate, created by 糖心vlog传媒鈩� Industry Reports. APAC Uterine Cancer Therapeutics & Diagnostics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

APAC Uterine Cancer Therapeutics & Diagnostics Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)